Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC)

被引:13
|
作者
Saccardi, Carlo [1 ]
Zovato, Stefania [2 ]
Spagnol, Giulia [1 ]
Bonaldo, Giulio [1 ]
Marchetti, Matteo [1 ]
Alessandrini, Lara [3 ]
Tognazzo, Silvia [2 ]
Guerriero, Angela [3 ]
Vitagliano, Amerigo [1 ]
Lagana, Antonio Simone [4 ]
Noventa, Marco [1 ]
机构
[1] Univ Padua, Dept Women & Childrens Hlth, Clin Gynaecol & Obstet, Via Giustiniani 3, I-3100 Padua, Italy
[2] IOV IRCCS, Veneto Inst Oncol, Familial Canc Clin & Oncoendocrinol, Padua, Italy
[3] Univ Padua, Dept Med DIMED, Surg Pathol & Cytopathol Unit, Padua, Italy
[4] Univ Insubria, Filippo Del Ponte Hosp, Dept Obstet & Gynaecol, Varese, Italy
关键词
BRCA mutation; Risk-reducing salpingo-oophorectomy; Serous tubal intraepithelial carcinoma; Occult cancer; Primary peritoneal carcinoma; Peritoneal carcinoma; MUTATION CARRIERS; FALLOPIAN-TUBE; PROPHYLACTIC OOPHORECTOMY; BREAST-CANCER; OVARIAN; WOMEN; COHORT; OCCULT;
D O I
10.1016/j.ygyno.2021.08.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Serous tubal intraepithelial carcinoma (STIC) is currently considered the precursor lesion of pelvic high-grade serous carcinoma. The management of STIC diagnosed after risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA1-2 variants remains unclear. The aim of our study was to evaluate the incidence of STIC, serous tubal intraepithelial lesions (STIL) and occult invasive cancer (OC) and to determine the longterm outcomes of these patients. Methods. We conducted a retrospective study of patients with BRCA 1-2 variants who underwent RRSO between January-2010 and Dicember-2020 at the Clinic of Gynaecology of University of Padova. Inclusion criteria: women with a negative pelvic examination at the last screening prior to RRSO, patients with fallopian tubes analysed using the SEE-FIM protocol. Exclusion criteria: patients with a positive gynaecologic screening or with ovarian/tubal cancer prior to RRSO. Results. We included 153 patients. STICs were diagnosed in 4 patients (2.6%) and STILs in 6 patients (3.9%). None of the patients with STIC underwent restaging surgery or adjuvant chemotherapy; all patients were followed closely every 6 months. None of the patients developed primary peritoneal carcinomas (PPCs) with a median FUP of 54.5 months (15-106). OC was diagnosed in 3 patients (2%). All patients with OC underwent staging surgery, and one patient developed a peritoneal carcinoma (PC) after 18 months by staging surgery. Conclusion(s). The incidence of STIC, STIL and OC after RRSO in BRCA1-2 variants was low. Our results demonstrated that long-term close surveillance in patients diagnosed with STIC should be considered a possible management strategy. (c) 2021 Elsevier Inc. All rights reserved.
引用
收藏
页码:364 / 370
页数:7
相关论文
共 50 条
  • [41] The psychosexual effects of risk-reducing bilateral salpingo-oophorectomy in female BRCA1/2 mutation carriers: A systematic review of qualitative studies
    Hickey, India
    Jha, Swati
    Wyld, Lynda
    GYNECOLOGIC ONCOLOGY, 2021, 160 (03) : 763 - 770
  • [42] Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know
    De Felice, F.
    Marchetti, C.
    Boccia, S. M.
    Romito, A.
    Sassu, C. M.
    Porpora, M. G.
    Muzii, L.
    Tombolini, V.
    Panici, P. Benedetti
    CANCER TREATMENT REVIEWS, 2017, 61 : 1 - 5
  • [43] Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers
    Claudia Marchetti
    Francesca De Felice
    Innocenza Palaia
    Giorgia Perniola
    Angela Musella
    Daniela Musio
    Ludovico Muzii
    Vincenzo Tombolini
    Pierluigi Benedetti Panici
    BMC Women's Health, 14
  • [44] Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience
    Harmsen, M. G.
    Arts-de Jong, M.
    Horstik, K.
    Manders, P.
    Massuger, L. F. A. G.
    Hermens, R. P. M. G.
    Hoogerbrugge, N.
    Woldringh, G. H.
    de Hullu, J. A.
    GYNECOLOGIC ONCOLOGY, 2016, 143 (01) : 113 - 119
  • [45] Stopping ovarian cancer screening in BRCA1/2 mutation carriers: Effects on risk management decisions & outcome of risk-reducing salpingo-oophorectomy specimens
    van Driel, Catheleine M. G.
    de Bock, Geertruida H.
    Arts, Henriette J. G.
    Sie, Aisha S.
    Hollema, Harry
    Oostervvijk, Jan C.
    Mourits, Marian J. E.
    MATURITAS, 2015, 80 (03) : 318 - 322
  • [46] Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers
    Havrilesky, Laura J.
    Moss, Haley A.
    Chino, Junzo
    Myers, Evan R.
    Kauff, Noah D.
    GYNECOLOGIC ONCOLOGY, 2017, 145 (03) : 549 - 554
  • [47] Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy
    C. A. Gabriel
    J. Tigges-Cardwell
    J. Stopfer
    J. Erlichman
    K. Nathanson
    S. M. Domchek
    Familial Cancer, 2009, 8 : 23 - 28
  • [48] Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction
    Stjepanovic, Neda
    Villacampa, Guillermo
    Nead, Kevin T.
    Torres-Esquius, Sara
    Melis, Guadalupe G.
    Nathanson, Katherine L.
    Teule, Alexandre
    Brunet, Joan
    y Cajal, Teresa R.
    Llort, Gemma
    Dienstmann, Rodrigo
    Rue, Montserrat
    Domchek, Susan M.
    Balmana, Judith
    EUROPEAN JOURNAL OF CANCER, 2020, 132 : 53 - 60
  • [49] Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations
    Solsky, Ian
    Chen, Jinbo
    Rebbeck, Timothy R.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (02) : 363 - 376
  • [50] Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study
    Mai, Phuong L.
    Huang, Helen Q.
    Wenzel, Lari B.
    Han, Paul K.
    Moser, Richard P.
    Rodriguez, Gustavo C.
    Boggess, John
    Rutherford, Thomas J.
    Cohn, David E.
    Kauff, Noah D.
    Phillips, Kelly-Anne
    Wilkinson, Kelly
    Wenham, Robert M.
    Hamilton, Chad
    Powell, Matthew A.
    Walker, Joan L.
    Greene, Mark H.
    Hensley, Martee L.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (01) : 131 - 139